Long-term ALS survival benefit with CNM-Au8 seen in trial analyses
Por um escritor misterioso
Descrição
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation - Advantx Pharmaceuticals Inc.
Synapticure on Science: Clinical Trials for Sporadic ALS
cdn.sanity.io/images/0vv8moc6/neurolive/6a4093ab3e
Clene: Still in the Running for ALS
News — ALS Hope Foundation
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
img_004.jpg
ALS clinical trials and studies • Les Turner ALS Foundation
TDP-43 as a therapeutic target in neurodegenerative diseases: Focusing on motor neuron disease and frontotemporal dementia - ScienceDirect
Synapticure on Science: Clinical Trials for Sporadic ALS
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension - eClinicalMedicine
Clene rockets on positive data for CNM-Au8 in ALS
Synapticure on Science: Clinical Trials for Sporadic ALS
Clene Nanomedicine (@CleneNano) / X
de
por adulto (o preço varia de acordo com o tamanho do grupo)